| Name | Title | Contact Details |
|---|
The Detroit Tigers are a Major League Baseball team based in Detroit, Michigan. One of the American Leagues eight charter franchises, the club was founded in Detroit in 1894. The Tigers have won four World Series championships (1935, 1945, 1968 and 1984) and have won the American League pennant 10 times. Since 2000, the team has played at Comerica Park. Find a listing of available jobs at http://detroit.tigers.mlb.com/careers/opportunities.jsp?c_id=det
Lockton Affinity is a division of Lockton Companies that focuses on underwriting and distributing specialty insurance products. It operates in markets that are outside the standard offerings, catering to unique insurance needs. Lockton Companies, the parent organization, is a global insurance brokerage known for its client-focused and family-owned approach.
Founded in 1982, ATKG specializes in tax, accounting, assurance and advisory services for a select client base of closely held businesses and large family groups. "ATKG" is the brand name under which ATKG LLP and ATKG Advisors LLC provide professional services. ATKG LLP and ATKG Advisors LLC practice as an alternative practice structure in accordance with the AICPA Code of Professional Conduct and applicable law, regulations, and professional standards. ATKG LLP is a licensed independent CPA firm that provides attest services to its clients, and ATKG Advisors LLC and its subsidiary entities provide tax and business consulting services to their clients. ATKG Advisors LLC and its subsidiary entities are not licensed CPA firms. The entities falling under the ATKG brand are independently owned and are not liable for the services provided by any other entity providing services under the ATKG brand. Our use of the terms "our firm" and "we" and "us" and terms of similar import, denote the alternative practice structure conducted by ATKG LLP and ATKG Advisors LLC.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.